GO:0050510 N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050510 describes the enzymatic activity that adds a beta-D-glucuronic acid residue to the N-acetylgalactosaminyl-proteoglycan acceptor during glycosaminoglycan chain elongation.
• This activity is essential for the biosynthesis of chondroitin sulfate and dermatan sulfate proteoglycans, which are key components of the extracellular matrix and cell surface.
• The enzyme belongs to the beta-1,3-glucuronyltransferase family, which includes GlcAT-I, GlcAT-P, and GlcAT-S, each with distinct substrate specificities and tissue distributions.
• Defects in glycosaminoglycan biosynthesis can lead to skeletal abnormalities, neurological disorders, and cancer progression.
• The HNK-1 carbohydrate epitope, synthesized by related glucuronyltransferases, is critical for neural development and synaptic plasticity.
• Research on GO:0050510 benefits from CRISPR-based knockout, knock-in, and overexpression models to dissect gene function and disease mechanisms.
Description
N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity (GO:0050510) is a molecular function that catalyzes the transfer of glucuronic acid from UDP-alpha-D-glucuronate to an N-acetylgalactosaminyl-proteoglycan acceptor, forming a beta-1,3 linkage. This reaction is a critical step in the elongation of glycosaminoglycan (GAG) chains on proteoglycans, which are abundant in the extracellular matrix and on cell surfaces. The resulting GAG chains, such as chondroitin sulfate and dermatan sulfate, modulate cell signaling, adhesion, and migration. The enzyme activity is also essential for the biosynthesis of the HNK-1 carbohydrate epitope, a sulfated glucuronic acid-containing glycan that plays key roles in neural cell recognition and plasticity. Researchers study GO:0050510 to understand how proteoglycan glycosylation contributes to development, tissue homeostasis, and disease. Alterations in GAG biosynthesis have been linked to skeletal dysplasias, neurodegenerative conditions, and cancer. The enzyme's specificity and regulation are governed by the expression of distinct glucuronyltransferase isoforms, such as GlcAT-I, GlcAT-P, and GlcAT-S, which exhibit different tissue distributions and substrate preferences. Understanding these enzymes at the molecular level provides insights into extracellular matrix biology and opens avenues for therapeutic intervention. This article integrates authoritative QuickGO data with published literature to provide a comprehensive overview of GO:0050510, covering its definition, mechanism, key genes, disease associations, and research methodologies, including CRISPR-based approaches for functional studies.
N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity At A Glance
| GO ID | GO:0050510 |
|---|---|
| GO term | N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity |
| Ontology | molecular_function |
| Synonym | chondroitin glucuronyltransferase II activity; alpha-D-glucuronate:N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-glucuronosyl-proteoglycan 3-beta-glucuronosyltransferase activity |
| Major function | Elongation of glycosaminoglycan chains on proteoglycans by adding glucuronic acid |
| Reaction | N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan + UDP-alpha-D-glucuronate = beta-D-glucuronosyl-(1,3)-N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan + UDP |
| Substrates | UDP-alpha-D-glucuronate; N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan |
| Products | Beta-D-glucuronosyl-(1,3)-N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan; UDP |
| Cellular location | Golgi apparatus membrane |
What Is GO:0050510?
GO:0050510, N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity, is defined as the catalysis of the reaction: N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan + UDP-alpha-D-glucuronate = beta-D-glucuronosyl-(1,3)-N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan + UDP. In simpler terms, it is the enzyme activity that adds a glucuronic acid sugar to a growing glycosaminoglycan chain on a proteoglycan, using UDP-glucuronic acid as the donor substrate. This activity is synonymous with chondroitin glucuronyltransferase II activity and alpha-D-glucuronate:N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-glucuronosyl-proteoglycan 3-beta-glucuronosyltransferase activity.
Why Is N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity Important in Cell Biology?
GO:0050510 is crucial for the biosynthesis of chondroitin sulfate and dermatan sulfate proteoglycans, which are major components of the extracellular matrix and cell surface. These proteoglycans regulate cell proliferation, differentiation, and migration, and their dysfunction is associated with developmental disorders, cancer, and neurological diseases. The enzyme activity also contributes to the formation of the HNK-1 epitope, a carbohydrate structure involved in neural cell adhesion and synaptic plasticity. Understanding this activity at the molecular level can inform therapeutic strategies targeting glycosaminoglycan-related pathologies.
• Essential for chondroitin sulfate and dermatan sulfate biosynthesis, impacting extracellular matrix structure and signaling.
• Required for HNK-1 carbohydrate epitope synthesis, which is critical for neural development and function.
• Mutations in glycosaminoglycan biosynthesis enzymes cause skeletal dysplasias and connective tissue disorders.
• Altered expression of glucuronyltransferases is observed in various cancers, affecting tumor progression and metastasis.
• The activity is involved in inflammatory responses and immune cell trafficking through proteoglycan-mediated chemokine gradients.
• Targeting this activity may offer therapeutic avenues for diseases characterized by abnormal glycosaminoglycan accumulation.
• It serves as a model for studying Golgi-resident glycosyltransferases and their regulation.
• CRISPR-based models enable precise dissection of gene function in glycosaminoglycan biology.
Molecular Mechanism of N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs the sugar donor and the growing sugar chain.
The enzyme binds UDP-alpha-D-glucuronate and the acceptor substrate, N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan. Structural studies of related glucuronyltransferases, such as GlcAT-I, reveal a conserved UDP-binding domain and a distinct acceptor-binding site that recognizes the terminal N-acetylgalactosamine residue. The specificity for the acceptor is determined by the enzyme's active site architecture, which accommodates the beta-1,4-linked glucuronic acid and the N-acetylgalactosamine moiety.
Catalytic Transfer of Glucuronic Acid
In simple terms: The enzyme transfers glucuronic acid onto the sugar chain.
The catalytic mechanism involves the nucleophilic attack of the acceptor's 3-hydroxyl group on the anomeric carbon of UDP-glucuronic acid, resulting in the formation of a beta-1,3-glycosidic bond and the release of UDP. This inverting glycosyltransferase reaction proceeds via a single displacement mechanism, as demonstrated for GlcAT-I. The enzyme requires a divalent metal ion, typically manganese, for optimal activity, which coordinates the UDP moiety and stabilizes the transition state.
Role in Glycosaminoglycan Chain Elongation
In simple terms: This step lengthens the sugar chain on proteoglycans.
The addition of glucuronic acid by GO:0050510 is a key elongation step in the biosynthesis of chondroitin sulfate and dermatan sulfate. Following the transfer, the chain can be further extended by alternating addition of N-acetylgalactosamine and glucuronic acid residues, catalyzed by other glycosyltransferases. The activity is essential for generating the characteristic repeating disaccharide units of these GAGs, which are subsequently sulfated to confer specific biological functions.
Regulation by Phosphorylation and Sulfation
In simple terms: Chemical tags on the sugar chain can affect enzyme activity.
The activity of beta-1,3-glucuronyltransferases can be modulated by modifications of the glycosaminoglycan-linkage region. Phosphorylation and sulfation of the linkage region determine the activity of human beta1,4-galactosyltransferase 7 and beta1,3-glucuronosyltransferase I, suggesting that similar regulatory mechanisms may influence GO:0050510. These modifications can alter substrate recognition and enzyme kinetics, thereby controlling GAG chain initiation and elongation.
Isoform-Specific Functions
In simple terms: Different versions of the enzyme do different jobs in cells.
The human genome encodes multiple beta-1,3-glucuronyltransferase isoforms, including GlcAT-I, GlcAT-P, and GlcAT-S, which exhibit distinct tissue distributions and substrate specificities. GlcAT-P and GlcAT-S are primarily involved in HNK-1 epitope synthesis, while GlcAT-I functions in the initiation of GAG chains. These isoforms are differentially transported and localized within the Golgi apparatus, contributing to the spatial and temporal regulation of glycosylation.
Key Genes Involved in GO:0050510 N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity
The following genes encode enzymes and related proteins that participate in or regulate N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity and associated glycosaminoglycan biosynthesis pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| B3GAT1 | Beta-1,3-glucuronyltransferase I; initiates GAG chain synthesis | Mutations linked to skeletal and neurological disorders |
| B3GAT2 | Beta-1,3-glucuronyltransferase II; involved in HNK-1 synthesis | Neural development and plasticity |
| B3GAT3 | Beta-1,3-glucuronyltransferase III; elongates GAG chains | Associated with connective tissue disorders |
| CHSY1 | Chondroitin sulfate synthase 1; co-polymerase with glucuronyltransferase activity | Skeletal development and cancer |
| CHPF | Chondroitin polymerizing factor; regulates GAG chain elongation | Extracellular matrix assembly |
| CSGALNACT1 | Chondroitin sulfate N-acetylgalactosaminyltransferase 1 | GAG biosynthesis and cancer progression |
| CSGALNACT2 | Chondroitin sulfate N-acetylgalactosaminyltransferase 2 | Neural development |
| UST | Uronyl 2-sulfotransferase; sulfates glucuronic acid residues | Modulates GAG function |
| CHST3 | Carbohydrate sulfotransferase 3; sulfates chondroitin | Skeletal dysplasia |
| CHST11 | Carbohydrate sulfotransferase 11; sulfates chondroitin | Cancer and development |
| CHST12 | Carbohydrate sulfotransferase 12; sulfates dermatan | Connective tissue biology |
| CHST13 | Carbohydrate sulfotransferase 13; sulfates chondroitin | GAG modification |
| CHST14 | Carbohydrate sulfotransferase 14; sulfates dermatan | Ehlers-Danlos syndrome |
| DSE | Dermatan sulfate epimerase; converts glucuronic acid to iduronic acid | Connective tissue disorders |
| DSEL | Dermatan sulfate epimerase-like | GAG diversity |
| XYLT1 | Xylosyltransferase 1; initiates GAG linkage region | Skeletal dysplasia |
| XYLT2 | Xylosyltransferase 2; initiates GAG linkage region | Connective tissue disorders |
How Is N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity Regulated?
The activity of N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase is regulated at multiple levels. Expression of the encoding genes, such as B3GAT3, is controlled by tissue-specific transcription factors and developmental signals. Post-translational modifications, including phosphorylation and sulfation of the glycosaminoglycan-linkage region, can modulate enzyme activity. Additionally, the availability of UDP-glucuronic acid and the Golgi environment influence catalytic efficiency. Isoform-specific trafficking and localization within the Golgi apparatus further contribute to regulation.
N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B3GAT3 | Spondyloepiphyseal dysplasia, connective tissue disorder | Knockout mouse, patient-derived iPSCs |
| B3GAT1 | Food hypersensitivity, insect venom allergy | Knockout cell lines, overexpression models |
| B3GAT2 | Neurological disorders, synaptic dysfunction | Conditional knockout mouse, neuronal cultures |
| CHSY1 | Skeletal dysplasia, cancer | Zebrafish knockout, cancer cell lines |
| CHST14 | Ehlers-Danlos syndrome | Patient fibroblasts, CRISPR knock-in |
Skeletal Dysplasias and Connective Tissue Disorders
Defects in glycosaminoglycan biosynthesis, including mutations in B3GAT3 and other enzymes, cause skeletal dysplasias such as spondyloepiphyseal dysplasia and connective tissue disorders. These conditions arise from impaired proteoglycan function in cartilage and bone, leading to short stature, joint abnormalities, and reduced bone density. The activity of GO:0050510 is critical for producing adequate chondroitin sulfate chains, and its deficiency can disrupt extracellular matrix integrity.
Neurological Disorders and HNK-1 Epitope
The HNK-1 carbohydrate epitope, synthesized by related glucuronyltransferases, is essential for neural cell adhesion, synaptic plasticity, and memory formation. Alterations in HNK-1 expression have been observed in neurodegenerative conditions and psychiatric disorders. Region-specific upregulation of HNK-1 glycan in the PRMT1-deficient brain suggests a link between epigenetic regulation and glycosylation in neural function. Furthermore, B3GAT1 gene expression has been associated with food hypersensitivity and insect venom allergy in mastocytosis patients, indicating a role in immune responses.
Cancer Progression and Metastasis
Altered expression of glycosaminoglycan biosynthesis enzymes, including glucuronyltransferases, is frequently observed in cancers. Chondroitin sulfate proteoglycans modulate tumor cell proliferation, migration, and invasion, and their remodeling in the tumor microenvironment promotes metastasis. Targeting GO:0050510 or related enzymes may therefore represent a therapeutic strategy for cancers dependent on GAG-mediated signaling.
From N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of B3GAT3 affect GAG chain elongation? | CRISPR knockout in HEK293 or chondrocyte cell lines |
| What is the effect of a point mutation in the catalytic domain? | CRISPR point mutation knock-in in cell lines |
| Can tagged B3GAT3 rescue glycosylation defects? | Knock-in of tagged B3GAT3 at endogenous locus |
| Does overexpression of B3GAT1 increase HNK-1 levels? | Lentiviral overexpression in neuronal cells |
| Which genes interact with B3GAT3 in GAG biosynthesis? | CRISPR library screening with glycan profiling |
| How does B3GAT3 deficiency alter the transcriptome? | RNA-seq of knockout vs wild-type cells |
How to Study the N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS glycomics | Glycan structures and sulfation patterns | Characterization of GAG chains in cells |
| Enzymatic activity assay | Glucuronyltransferase activity | Kinetic analysis of recombinant enzymes |
| CRISPR knockout | Gene function loss | Phenotypic analysis of GAG biosynthesis |
| CRISPR knock-in | Tagged or mutant protein expression | Localization and interaction studies |
| RNA-seq | Transcriptional changes | Pathway analysis in knockout models |
| Immunofluorescence | Protein and glycan localization | Golgi and cell surface imaging |
| Flow cytometry | Cell surface glycan expression | HNK-1 detection in neural cells |
| Western blot | Protein expression levels | Validation of knockout/overexpression |
Glycan Profiling and Mass Spectrometry
Mass spectrometry-based glycomics and glycan profiling are essential for characterizing the products of GO:0050510. These methods can detect and quantify chondroitin sulfate and dermatan sulfate chains, as well as HNK-1 epitopes, in cell lysates or tissues. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) enables structural elucidation of glycosaminoglycan disaccharides and their sulfation patterns.
Enzymatic Activity Assays
In vitro enzyme assays using recombinant glucuronyltransferases and synthetic acceptor substrates measure the transfer of glucuronic acid from UDP-glucuronic acid. These assays typically employ radiolabeled or fluorescently labeled UDP-glucuronic acid and detect product formation by chromatography or mass spectrometry. Such assays are used to determine kinetic parameters and substrate specificity of GO:0050510.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 knockout, knock-in, and point mutation models enable precise dissection of gene function in glycosaminoglycan biosynthesis. Knockout of B3GAT3 or related genes in cell lines or animal models can reveal their roles in GAG chain elongation and downstream biological processes. Knock-in of tagged or mutant alleles allows for tracking protein localization and function in vivo.
Antibody-Based Detection and Imaging
Antibodies against HNK-1 and other glycosaminoglycan epitopes are used in immunofluorescence, immunohistochemistry, and Western blotting to detect the products of GO:0050510 in cells and tissues. These methods provide spatial information about glycosylation patterns and can be combined with confocal microscopy to study Golgi localization.
How CRISPR Can Be Used to Study GO:0050510 N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity
Knockout
CRISPR-Cas9 knockout of B3GAT3 or other glucuronyltransferase genes in cell lines such as HEK293 or CHO cells abolishes GO:0050510 activity, leading to truncated glycosaminoglycan chains and altered proteoglycan function. These models are used to study the consequences of GAG deficiency on cell signaling, adhesion, and extracellular matrix assembly.
Point Mutation
Introducing point mutations in the catalytic domain of B3GAT3 via CRISPR-Cas9 homology-directed repair allows researchers to dissect the contribution of specific amino acid residues to substrate binding and catalysis. Such models can mimic human disease-associated mutations and reveal genotype-phenotype relationships.
Knock-in
Knock-in of epitope-tagged B3GAT3 or fluorescent reporters at the endogenous locus enables real-time tracking of enzyme localization and dynamics within the Golgi apparatus. This approach also facilitates affinity purification of the enzyme complex for interactome studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of B3GAT3 and related genes increases GO:0050510 activity, leading to enhanced GAG chain elongation and HNK-1 expression. Overexpression models are useful for studying gain-of-function effects in neural development and cancer.
How EDITGENE Supports N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity Research
Researchers studying N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosaminoglycan biosynthesis, neural development, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for functional validation.
Contact EDITGENE today to design your custom CRISPR model for N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity research.
Frequently Asked Questions About N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity
What is N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity?
It is the enzyme activity (GO:0050510) that adds a glucuronic acid sugar to a growing glycosaminoglycan chain on proteoglycans, using UDP-glucuronic acid as the donor.
What genes are involved in N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity?
Genes such as B3GAT1, B3GAT2, B3GAT3, CHSY1, and CHPF encode enzymes that participate in this activity or related glycosaminoglycan biosynthesis steps.
What is the role of GO:0050510 in chondroitin sulfate synthesis?
GO:0050510 catalyzes a key elongation step in chondroitin sulfate biosynthesis by adding glucuronic acid to the N-acetylgalactosaminyl-proteoglycan acceptor.
Which diseases are associated with defects in this enzyme activity?
Defects can lead to skeletal dysplasias, connective tissue disorders, neurological conditions, and cancer progression.
How is N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity regulated?
It is regulated by gene expression, post-translational modifications of the linkage region, and Golgi localization of enzyme isoforms.
What is the HNK-1 epitope and how is it related to GO:0050510?
HNK-1 is a sulfated glucuronic acid-containing glycan synthesized by related glucuronyltransferases; it is critical for neural cell adhesion and plasticity.
Can CRISPR be used to study this enzyme activity?
Yes, CRISPR knockout, knock-in, and point mutation models enable precise functional studies of genes encoding this activity.
What methods are used to measure N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity?
Enzymatic assays with UDP-glucuronic acid, mass spectrometry glycomics, and antibody-based detection are commonly used.
What are the substrates of GO:0050510?
The substrates are UDP-alpha-D-glucuronate and N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan.
How does B3GAT3 deficiency affect the extracellular matrix?
B3GAT3 deficiency impairs glycosaminoglycan chain elongation, leading to defective proteoglycan function and extracellular matrix integrity.
Conclusion
N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity (GO:0050510) is a fundamental enzymatic function in glycosaminoglycan biosynthesis, essential for proteoglycan assembly and HNK-1 epitope formation. Its roles in skeletal development, neural function, and cancer highlight its biomedical importance. Advances in CRISPR-based genome editing and glycomics are accelerating our understanding of this activity and its associated genes, offering new opportunities for therapeutic intervention.
References
- 1. Kawade H et al.. 2021. Tissue-Specific Regulation of HNK-1 Biosynthesis by Bisecting GlcNAc.. Molecules 26(17) PMID: 34500611
- 2. Kizuka Y et al.. 2012. Regulated expression and neural functions of human natural killer-1 (HNK-1) carbohydrate.. Cell Mol Life Sci 69(24):4135-47 PMID: 22669261
- 3. Fan C et al.. 2023. UDP-glucuronosyltransferase is involved in susceptibility of Chironomus kiiensis Tokunaga, 1936 (Diptera: Chironomidae) to insecticides.. Ecotoxicol Environ Saf 263:115353 PMID: 37586199
- 4. Gulberti S et al.. 2005. Modifications of the glycosaminoglycan-linkage region of proteoglycans: phosphorylation and sulfation determine the activity of the human beta1,4-galactosyltransferase 7 and beta1,3-glucuronosyltransferase I.. ScientificWorldJournal 5:510-4 PMID: 16075146
- 5. Pedersen LC et al.. 2000. Heparan/chondroitin sulfate biosynthesis. Structure and mechanism of human glucuronyltransferase I.. J Biol Chem 275(44):34580-5 PMID: 10946001
- 6. Hashimoto M et al.. 2020. Region-specific upregulation of HNK-1 glycan in the PRMT1-deficient brain.. Biochim Biophys Acta Gen Subj 1864(3):129509 PMID: 31884067
- 7. Górska A et al.. 2016. The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis.. Arch Immunol Ther Exp (Warsz) 64(6):497-503 PMID: 27086366
- 8. Kizuka Y et al.. 2009. Distinct transport and intracellular activities of two GlcAT-P isoforms.. J Biol Chem 284(14):9247-56 PMID: 19181664
